Abstract:Background: For patients with symptomatic intracranial and vertebral artery stenosis who receive endovascular treatment, in-stent restenosis (ISR) is associated with the recurrence of ischemic stroke. This study evaluated a drug-eluting stent (DES) vs. bare metal stent (BMS) for the treatment of symptomatic intracranial and vertebral artery stenosis. Methods: The trial was a multicenter, 1:1 randomized, prospective feasibility clinical trial with 10 participating centers in China from March 2014 to October 2015. Eligible patients had symptomatic intracranial and vertebral artery stenosis (70%−99%) and had medical drug treatment failure. The primary endpoint was the rate of in-stent restenosis at 180 days of randomization. The secondary endpoint was a composite of the following two outcomes: (1) ischemic stroke or transient cerebral ischemia (TIA) in the same territory as the presenting event (distal to the target lesion) between 30 days and 1 year after randomization and (2) successful stent implantation. The safety outcome was the presence of stroke in any territory and death within 30 days of randomization or adverse events. Group t -tests or Wilcoxon rank-sum tests were used for the intergroup comparison of quantitative data according to the data distribution. The chi-square test or exact probability method was used for the classification data. The Wilcoxon rank-sum test or CMH test was used for the categorical data. Results: We enrolled 188 patients at 10 medical centers in China (92 assigned to the DES group and 96 to the BMS group). The mean age of the 188 study participants was 61.6 years (range, 38–75 years); 152 participants (80.9%) were male. There were 28 patients (43.8%) with an ISR at 180 days in the BMS group and 10 patients (14.5%) in the DES group [risk difference, 29.3% (95% CI, 14.5%−44.0%); P = 0.001]. The percent of patients with ischemic stroke or TIA in the same territory between 30 days and 1 year was 5.2% (5/96) in the BMS group and 2.2% (2/92) in the DES group [risk difference, 3.0%; (95% CI, −2.3% to 8.2%); P = 0.354]. The percent of patients with successful stent implantation was 99.0% (95/96) in the BMS group and 97.8% (90/92) in the DES group [risk difference, 1.1%; (95% CI, −1.7% to 3.9%); P = 0.584]. In total, five patients (5.2%) in the BMS group and three patients (3.3%) in the DES group [risk difference, 1.9%; (95% CI, −2.3% to 6.1%); P = 0.721] had stroke in any territory and death within the 30-day follow-up. Total adverse events occurred 167 times in 72 patients (75.0%) in the BMS group compared with 114 times in 59 patients (64.1%) in the DES group [risk difference, 10.9%; (95% CI, −0.1% to 21.7%); P = 0.115]. Conclusions: Among patients with symptomatic intracranial arterial stenosis and vertebral artery stenosis, the use of a drug-eluting stent compared with a bare metal stent resulted in a decreased risk of ISR, similar successful stent implantation, and similar adverse events. These findings support the use of a drug-eluting stent for patients with symptomatic intracranial arterial stenosis and vertebral artery stenosis. Clinical Trial Registration: http://www.chictr.org.cn/showproj.aspx?proj=148272, identifier: ChiCTR2200055925.

[Clinical and Angiographic Outcomes of Coronary Drug-Eluting Stenting in Treating Vasospastic Angina Patients with Severe Organic Stenosis].

Cause Analysis and Treatment of Vertebral Artery Stenosis Angioplasty Restenosis

Clinical Outcomes and Risk Factors of Coronary Artery Aneurysms after Successful Percutaneous Coronary Intervention and Drug-Eluting Stent Implantation for Chronic Total Occlusions

Prognosis Of Unprotected Left Main Coronary Artery Stenting And The Factors Affecting The Outcomes In Chinese

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

Percutaneous Treatment with Drug-Eluting Stent Vs Bypass Surgery in Patients Suffering from Chronic Stable Angina with Multivessel Disease Involving Significant Proximal Stenosis in Left Anterior Descending Artery

Comparison of One-Year Clinical Outcomes Between Intravascular Ultrasound-Guided Versus Angiography-Guided Implantation of Drug-Eluting Stents for Left Main Lesions: A Single-Center Analysis of A 1,016-Patient Cohort

The long-term clinical outcomes of intravascular ultrasound-guided versus angiography-guided coronary drug eluting stent implantation in long de novo coronary lesions: A systematic review and meta-analysis

Risk Factors and Clinical Outcome of Coronary Artery Aneurysms Developed after Drug-Eluting Stent Implantation

Clinical efficacy and follow up of drug eluting stent treatment for 120 unprotected left main coronary artery lesions

Effect of a Drug-Eluting Stent vs. Bare Metal Stent for the Treatment of Symptomatic Intracranial and Vertebral Artery Stenosis

Safety and Efficacy of Rapamycin-Eluting Vertebral Stents in Patients With Symptomatic Extracranial Vertebral Artery Stenosis

Effect of Drug Eluting stent Implantation in the Treatment of Coronary Artery In-stent Restenosis in a Longterm Clinical Follow-up

A Comparison of Different Endovascular Treatment for Vertebral Artery Origin Stenosis.

Endovascular treatment of extracranial atherosclerotic disease involving the vertebral artery origins: a comparison of drug-eluting and bare-metal stents

Prospective Clinical Study on Direct Coronary Stenting

Effectiveness of drug eluting stents in patients with small coronary artery lesions

Nine-month Angiographic and Two-year Clinical Follow-up of Novel Biodegradable-polymer Arsenic Trioxide-eluting Stent Versus Durable-polymer Sirolimus-eluting Stent for Coronary Artery Disease

Long-term Outcomes Following Drug-Eluting Stent Implantation in Unprotected Left Main Bifurcation Lesions.

Clinical and Angiographic Outcome after Sirolimus-Eluting Stent Implantation in Aorto-Ostial Lesions.

Stenting of vertebral artery origin atherosclerosis in high-risk patients: bare or coated? A single-center consecutive case series